Evidence map›Paper›PMID 36750455›Full record

ArticleAnnals of dermatology2023

A Randomized, Prospective, Split-Face Pilot Study to Evaluate the Safety and Efficacy of 532-nm and 1,064-nm Picosecond-Domain Neodymium:Yttrium-Aluminum-Garnet Lasers Using a Diffractive Optical Element for Non-Ablative Skin Rejuvenation: Clinical and Histological Evaluation.

Hye Sung Han, Jun Ki Hong, Su Jung Park, Byung Cheol Park, Kui Young Park

Open access · diamondAbstract read
In one paragraph

Article in Annals of dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Hye Sung HanDepartment of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea.ORCID https://orcid.org/0000-0002-3556-0740
Jun Ki HongDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-5277-5823
Su Jung ParkDepartment of Dermatology, Chungnam National University Sejong Hospital, Sejong, Korea.ORCID https://orcid.org/0000-0001-9314-6401
Byung Cheol ParkDepartment of Dermatology, College of Medicine, Dankook University, Cheonan, Korea.ORCID https://orcid.org/0000-0002-5449-8313
Kui Young ParkDepartment of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea. kyky@cau.ac.kr.ORCID https://orcid.org/0000-0001-5965-1754
Chung-Ang University · KRChungnam National University · KRDankook University · KRSeoul National University Bundang Hospital · KR

Funding

Laseroptek Inc
6 · The paper itself

Abstract

backgroundThe advent of fractionated picosecond (ps) lasers has provided an opportunity to explore new ways of creating microinjuries in the skin to induce skin rejuvenation.

objectiveTo compare the efficacy and safety of diffractive optical element (DOE)-assisted ps neodymium: yttrium-aluminum-garnet (Nd:YAG) lasers with 532-nm and 1,064-nm wavelengths (532-nm and 1,064-nm Nd:YAG P-DOE) using a novel fractional handpiece for the treatment of photoaged skin.

methodsAn

resultsBased on the histological evaluation using

conclusionAt a preliminary level, this study revealed that 532-nm and 1,064-nm ps Nd:YAG lasers using DOE fractional technology may improve photoaged skin. In conclusion, 532-nm Nd:YAG P-DOE may be especially beneficial for skin with epidermal pigmentary lesions.

Indexed as

AsianLasersRejuvenationSkin aging

Identifiers

PMID36750455
PMCPMC9905855
OpenAlexW4318452811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.